HK1200166A1 - 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)- - Google Patents

3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)-

Info

Publication number
HK1200166A1
HK1200166A1 HK15100542.6A HK15100542A HK1200166A1 HK 1200166 A1 HK1200166 A1 HK 1200166A1 HK 15100542 A HK15100542 A HK 15100542A HK 1200166 A1 HK1200166 A1 HK 1200166A1
Authority
HK
Hong Kong
Prior art keywords
parp
isoquinolin
phenyl
derivatives
inhibitors
Prior art date
Application number
HK15100542.6A
Other languages
English (en)
Chinese (zh)
Inventor
‧帕裴奧
‧西爾拉
‧達內羅
‧斯科拉羅
‧祖科多
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1200166A1 publication Critical patent/HK1200166A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100542.6A 2011-11-25 2015-01-16 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)- HK1200166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (fr) 2011-11-25 2012-11-20 Dérivés 3-phényl-isoquinolin-1(2h)-one en tant qu'inhibiteurs de parp-1

Publications (1)

Publication Number Publication Date
HK1200166A1 true HK1200166A1 (en) 2015-07-31

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100542.6A HK1200166A1 (en) 2011-11-25 2015-01-16 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)-

Country Status (15)

Country Link
US (1) US9422243B2 (fr)
EP (1) EP2788328B1 (fr)
JP (1) JP6106182B2 (fr)
KR (1) KR20140097457A (fr)
CN (1) CN103946214B (fr)
AU (1) AU2012342562B2 (fr)
BR (1) BR112014012031A2 (fr)
CA (1) CA2856759A1 (fr)
CL (1) CL2014001323A1 (fr)
EA (1) EA027800B1 (fr)
ES (1) ES2676068T3 (fr)
HK (1) HK1200166A1 (fr)
IN (1) IN2014CN04671A (fr)
MX (1) MX2014006015A (fr)
WO (1) WO2013076090A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865511A1 (fr) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Composes 3-aryl -5-substitue-isoquinolin -1-one et leur utilisation therapeutique
DK3044221T3 (en) * 2013-09-11 2018-04-23 Institute Of Cancer Res Royal Cancer Hospital The 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
WO2015108986A1 (fr) * 2014-01-16 2015-07-23 Clovis Oncology, Inc. Utilisation d'inhibiteurs de parp pour traiter des patients atteints de cancer du sein ou de l'ovaire présentant une perte d'hétérozygotie
CN108349936B (zh) 2015-11-06 2021-10-01 纽罗克里生物科学有限公司 作为毒蕈碱性受体4拮抗剂的化合物
WO2023242302A1 (fr) 2022-06-15 2023-12-21 Astrazeneca Ab Polythérapie pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528376A (ja) * 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
JPWO2004009556A1 (ja) 2002-07-24 2005-11-17 杏林製薬株式会社 ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
WO2009104802A1 (fr) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Nouveaux dérivés d'aminopyridine présentant une action inhibitrice sélective d'aurora a
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物

Also Published As

Publication number Publication date
US9422243B2 (en) 2016-08-23
MX2014006015A (es) 2014-06-04
US20140336192A1 (en) 2014-11-13
EA201491026A1 (ru) 2014-11-28
EP2788328B1 (fr) 2018-01-31
CN103946214B (zh) 2016-08-17
BR112014012031A2 (pt) 2017-05-30
ES2676068T3 (es) 2018-07-16
EA027800B1 (ru) 2017-09-29
KR20140097457A (ko) 2014-08-06
CL2014001323A1 (es) 2014-09-05
EP2788328A1 (fr) 2014-10-15
AU2012342562A1 (en) 2014-07-10
IN2014CN04671A (fr) 2015-09-18
CN103946214A (zh) 2014-07-23
JP2014533709A (ja) 2014-12-15
AU2012342562B2 (en) 2017-02-23
CA2856759A1 (fr) 2013-05-30
WO2013076090A1 (fr) 2013-05-30
JP6106182B2 (ja) 2017-03-29

Similar Documents

Publication Publication Date Title
IL252184B (en) Heterocycloamines as pi3k inhibitors
HK1195552A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
HK1198764A1 (zh) 大環 激酶抑制劑
HK1199880A1 (en) Benzonitrile derivatives as kinase inhibitors
ZA201203326B (en) Imidazopyridine derivatives as jak inhibitors
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
EP2552208A4 (fr) Imidazolyl-imidazoles en tant qu'inhibiteurs de kinase
EP2552214A4 (fr) Pyrazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201400374B (en) 4-piperidinyl compounds for use as tankyrase inhibitors
EP2552211A4 (fr) Indazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
HK1210771A1 (en) Azaindole derivatives which act as pi3k inhibitors
EP2685992A4 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
HK1212331A1 (en) 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4--
HK1200166A1 (en) 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors parp-1 3---1(2h)-
PL2760867T3 (pl) Makrocykliczne inhibitory kinaz FLT3